Healthcare / BiotechnologyNasdaqCM
$2.48
-0.21 (-7.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.9M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$38M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.6M · FCF $-14.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-9.6M | $-9.6M | $-12.9M | $-42.4M | $-9.8M | $-19.7M | $-25.5M | $-39.4M |
| EBITDA | $-16.7M | $-16.7M | $-11.3M | $-18.1M | $-15.3M | — | — | — |
| EPS | -0.79 | -0.79 | -1.35 | -5.71 | -1.62 | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | — | — | — | 0.01 | 0.00 | — | — | — |
| Current Ratio | 14.96 | 14.96 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-14.9M | $-14.9M | $-12.4M | $-15.9M | $-17.2M | — | — | — |
| Returns | ||||||||
| ROE | -14.4% | -14.4% | -20.8% | -62.4% | -9.1% | -35.4% | -196.3% | -356.4% |
| Valuation | ||||||||
| P/B | 0.45 | 0.45 | 0.52 | 0.29 | 0.42 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | 41.5% | 41.5% | 76.4% | -252.5% | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.35 → -0.79
Residual
-11.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.